CoChat

A review of clinical treatment considerations of donepezil in severe Alzheimer's disease

Open access
Adlimoghaddam, Aida, Neuendorff, Melanie, Roy, Banibrata, Albensi, Benedict C. · 2018 · CNS Neuroscience & Therapeutics
Cited by 154

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Summary: Background: Alzheimer's disease (AD) is a neurodegenerative disorder that affects over 45 million people worldwide. Patients with severe AD require help with daily activities and show severe memory impairment. Currently, donepezil is one of two drugs approved by FDA and Health Canada for the treatment of severe AD (MMSE score <10). It is prescribed as 5 or 10 mg/d and an FDA‐approved 23‐mg/d dose. Method: This review will discuss risks and benefits of donepezil at these doses in severe AD. Articles were identified using PubMed using the Me SH terms “donepezil” AND “Alzheimer Disease” AND “severe.” Three double‐blind, placebo‐controlled, randomized studies, one post hoc analysis, and one subgroup analysis were selected. Results: Donepezil was found to benefit patients in cognition and global functioning. The most consistent improvement was in severe impairment battery (SIB) scores. However, more patients treated with high dosage of donepezil discontinued their treatment due to various adverse events (AE s). Conclusion: Clinicians must weigh benefits against adverse events when determining the course of therapy, as recommendations for cholinesterase inhibitors in advanced AD remain unclear and vary with different guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cns.13035

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 154

Metadata

Authors
Adlimoghaddam, A., Neuendorff, M., Roy, B., & Albensi, B. C.
Venue
CNS Neuroscience & Therapeutics
Publisher
Wiley
Published
2018-07-29
Volume
24
Issue
10
Pages
876-888
ISSN
  • 1755-5930 (ISSN-L)
  • 1755-5949
OpenAlex
W2885800496
Cited by
154
References
11
FWCI
5.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.